Abstract 1858P
Background
Identifying the patient's discomfort and unmet needs is crucial for providing effective care. However, accurately understanding the patient's discomfort can be challenging due to various limitations in the medical field, and in some cases, their discomfort may be underestimated. To better understand the difficulties faced by cancer patients, we implemented Social Listening to identify areas where improved treatment may be provided.
Methods
From October 1, 2021 to September 30, 2022, we gathered online data related to cancer and anti-cancer treatments. Using NetBase as our social listening platform, we filtered out irrelevant and commercial content from the collected data.
Results
A total of 169,575 social mentions related to cancer and anticancer treatment were collected. Among them, 12% (n=20,899) addressed the challenges experienced by patients following a cancer diagnosis. These challenges were further categorized based on the content of social media posts, with 52% focusing on physical difficulties, 42% on emotional challenges, and 6% on difficulties related to daily life. Emotional difficulties such as worry, denial, depression, fear, and anxiety were prevalent among cancer patients, with variations in priority depending on the time of diagnosis, treatment, and post-treatment stages. Of the 16,743 social media discussions related to cancer care, only 9% were related to managing emotional stress. A majority (84%) of discussions related to mental health management involved receiving psychiatric treatment, with the remaining 16% focusing on self-help groups, communication with others, meditation, hobbies, and religious practices.
Conclusions
Emotional burdens, along with physical difficulties, were frequently discussed on social media. However, there appeared to be a relative lack of focus on the management of emotional burdens. Considering the known association between emotional management and cancer treatment outcomes, it is imperative for physicians to prioritize their patients' emotional well-being and offer appropriate support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korean Society of Medical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05